ArticleFrontiers in oncology2025
Multimodality treatment on gastric cancer with liver metastasis: case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Advanced gastric cancer has a devastating prognosis, However, the optimal treatment for gastric cancer patients with multiple liver metastases(GCLM) remains yet to be fully elucidated. Cryoablation is a novel therapeutic approach that has the potential to induce tumor necrosis and elicit anti-tumor immune responses. Case presentation: A 44-year-old male was diagnosed with advanced gastric adenocarcinoma. Despite undergoing multiple lines of systemic therapy and repeated locoregional treatments, the patient exhibited rapid tumor progression. Subsequent treatment with PD-1 inhibitors demonstrated limited efficacy. However, following the innovative application of cryoablation to eradicate a more significant lesion within the liver metastases, the patient achieved a partial response and experienced 15 months of progression-free survival (PFS) with the combined use of PD-1 inhibitors and chemotherapy at the time of this report. Conclusion: Cryoablation combined with immunotherapy may provide potential benefits for specific patients and offer a meaningful therapeutic strategy for patients with advanced gastric cancer and liver metastases, which is worthy of further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.